Trans-anethole pretreatment ameliorates hepatic ischemia–reperfusion injury via regulation of soluble epoxide hydrolase
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110809 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Jiansen Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: First Central Clinical Institute, Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Reperfusion Injury, Epoxide Hydrolases, Liver, Anisoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tianjin Municipal Health Commission, Natural Science Foundation of Tianjin Municipality, Tianjin Municipal Bureau of Public Health.
Abstract (Originalsprache)
Hepatic ischemia reperfusion injury (IRI) is a risk factor for early graft nonfunction and graft rejection after liver transplantation (LT). The process of liver IRI involves inflammatory response, oxidative stress, apoptosis and other pathophysiological processes. So far, there is still a lack of effective drugs to ameliorate liver IRI. Trans-anethole (TA) is an aromatic compound. Many medications as well as natural foods contain TA. TA has multiple effects such as anti-inflammation, anti-oxidative stress and anti-apoptosis. However, the mechanism of TA pretreatment in liver IRI is unclear. The mice hepatic IRI model was constructed after gavage pretreatment with TA (10 mg/kg, 20 mg/kg, 40 mg/kg) for 7 consecutive days. Our study confirmed that TA pretreatment significantly improve liver function and reduce serum AST, ALT in hepatic IRI. HE staining showed that TA pretreatment alleviated liver injury. Meanwhile, TA (20 mg/kg) pretreatment attenuated hepatocyte apoptosis in hepatic IRI. In addition, TA (20 mg/kg) pretreatment reduced the inflammatory factors TNF-α, IL-6 and infiltration of CD11b positive cells in liver tissues during hepatic IRI in mice. TA pretreatment also alleviated oxidative stress in mice hepatic IRI. Our study further indicated that TA pretreatment attenuated mice hepatic IRI through inhibiting NLRP3 inflammasome activation via regulation of soluble epoxide hydrolase (sEH). This study provides a novel and effective potential drug with few side effects for easing liver IRI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Central Clinical Institute, Tianjin Medical University, Tianjin, China.
- Research Institute of Transplant Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China.
- National Health Commission's Key Laboratory for Critical Care Medicine, Tianjin First Central Hospital, Tianjin, China.
- School of Medicine, Nankai University, Tianjin, China.
- Research Institute of Transplant Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China; Tianjin Key Laboratory for Organ Transplantation, Tianjin First Central Hospital, Tianjin, China; Organ Trans…
Förderung
- Tianjin Municipal Health Commission
- Natural Science Foundation of Tianjin Municipality
- Tianjin Municipal Bureau of Public Health
Zitieren
APA
Lu, J., Hou, W., Yang, S., Chen, D., Wang, F., Liu, L., & Shen, Z. (2023). Trans-anethole pretreatment ameliorates hepatic ischemia–reperfusion injury via regulation of soluble epoxide hydrolase. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110809
Vancouver
Lu J, Hou W, Yang S, Chen D, Wang F, Liu L, et al. Trans-anethole pretreatment ameliorates hepatic ischemia–reperfusion injury via regulation of soluble epoxide hydrolase. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110809
BibTeX
@article{Lu2023,
author = {Lu, Jiansen and Hou, Wen and Yang, Shuang and Chen, Decheng and Wang, Fei and Liu, Lei and Shen, Zhongyang},
title = {Trans-anethole pretreatment ameliorates hepatic ischemia–reperfusion injury via regulation of soluble epoxide hydrolase},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110809}
}
EUVIMED